CN3 COST-EFFECTIVENESS OF IMATINIB VERSUS INTERFERON (IFN-a) PLUS LOW-DOSE CYTARABINE (ARA-C) FOR NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) IN THE THE NETHERLANDS
Abstract
Authors
MT Groot KD Anstrom SD Reed CA Uyl-de Groot